Everest Medicines to Participate in Investor Conferences
Biopharmaceutical company Everest Medicines announced its participation in upcoming investor conferences. The company's President and CFO, Ian Woo, will represent the firm at these events.
Shanghai-based biopharmaceutical company Everest Medicines (HKEX 1952.HK) announced that its President and Chief Financial Officer, Ian Woo, will participate in two upcoming investor conferences. The company focuses on the discovery, development, manufacturing, and commercialization of innovative therapeutics.
Mr. Woo is scheduled to participate in Morgan Stanley's "Biotech Without Borders Series" on Tuesday, July 28, 2026, in a fireside chat format. A webcast of this session will be available. Following this, he will attend Evercore's "2nd Annual China Biotech Summit" on Tuesday, August 18, 2026, held at The Ritz-Carlton Shanghai, Pudong, which will include a presentation and Q&A session.
Everest Medicines' therapeutic areas of focus include autoimmune diseases, ophthalmology, critical care, and cardio-renal-metabolic diseases. The company operates a fully integrated commercialization platform and leverages its proprietary mRNA platform for pipeline advancement, including mRNA in vivo CAR-T and mRNA cancer vaccines, alongside its global expansion strategy.